Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity
Shots:
- The P-III (SUMMIT) trial assessed tirzepatide (5mg, 10mg or 15mg) vs PBO to treat patients (n=731) with heart failure having preserved ejection fraction (HFpEF) & obesity, with/without T2D
- Study showed a -38% relative reduced risk in time-to-first heart failure occurrence at 104wks. median follow-up plus 24.8 points vs 15.0 points (efficacy estimand) & 19.5 points vs 12.7 points (treatment-regimen estimand) improvements in heart failure symptoms & physical limitations from baseline
- The 2EPs were also reached, showing 15.7% vs 2.2% (efficacy estimand) & 13.9% vs 2.2% (treatment-regimen estimand) reduced body wt. Data will be highlighted & submitted to the US FDA & other regulatory bodies later in 2024
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports Detailed Data from the P-III (SURMOUNT-OSA) Trial of Tirzepatide to Treat Obstructive Sleep Apnea
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
